<br />
PROMOTIONAL<br />
ADVERT<br />
HEMATOLOGY<br />
EMJ Hematol. 2019 Suppl 2 • europeanmedical-journal.com<br />
INSIDE<br />
Improving Patient Outcomes in Acute<br />
Leukaemias: Navigating Complex<br />
Treatment Decisions in an Era of<br />
Novel Therapies<br />
Sponsored by Pfizer<br />
The symposium and the publication of this article was funded by Pfizer. Pfizer and the authors have reviewed the<br />
article for medical accuracy and had editorial input.<br />
Adverse events should be reported. Click below to view the following:<br />
Reporting forms and information can be<br />
Prescribing information: Mylotarg® (gemtuzumab ozogamicin)<br />
found at https:/yellowcard.mhra.gov.uk/<br />
Adverse events should also be reported to Prescribing information: Cytarabine (cytosine arabinoside)<br />
Pfizer Limited on 01304 616161 Prescribing informat<a title="EMJ Hematol. 2019 Suppl 2 page 1" href="http://viewer.zmags.com/publication/a9f3f9f8?page=1"> PROMOTIONAL ADVERT HEMATOLOGY EMJ Hematol. 2019 </a>
<a title="EMJ Hematol. 2019 Suppl 2 page 2" href="http://viewer.zmags.com/publication/a9f3f9f8?page=2"> Improving Patient Outcomes in Acute Leukaemias: </a>
<a title="EMJ Hematol. 2019 Suppl 2 page 3" href="http://viewer.zmags.com/publication/a9f3f9f8?page=3"> three clinical cases. The first case of an older p</a>
<a title="EMJ Hematol. 2019 Suppl 2 page 4" href="http://viewer.zmags.com/publication/a9f3f9f8?page=4"> 1989—1994 1995—2000 2001—20</a>
<a title="EMJ Hematol. 2019 Suppl 2 page 5" href="http://viewer.zmags.com/publication/a9f3f9f8?page=5"> MRD is most important for assessing prognosis.14 </a>
<a title="EMJ Hematol. 2019 Suppl 2 page 6" href="http://viewer.zmags.com/publication/a9f3f9f8?page=6"> Regarding use of the BCR-ABL kinase inhibitor pon</a>
<a title="EMJ Hematol. 2019 Suppl 2 page 7" href="http://viewer.zmags.com/publication/a9f3f9f8?page=7"> References 1. Dinmohamed AG et al. Improved </a>